301130.SZ
西点药业
SZSE · Healthcare · C 制造业 · CN
CNY 33.09
+5.45%Year over year
Reported trailing growth
- Revenue
- -1.4%
- EBITDA
- —
- EBIT
- -45.6%
- EPS
- -32.2%
- Free cash flow
- +70.3%
- Operating cash flow
- -15.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -2.8%
- EBITDA
- -7.7%
- EBIT
- -27.1%
- Net income
- -18.7%
- EPS
- -18.3%
- Free cash flow
- +78.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026